Guselkumab has shown superior long-term efficacy when compared to secukinumab for the management of moderate to severe psoriasis. A phase 3 randomised controlled trial of the two biologics involved more than 1,000 adult patients from nine countries including Australia. Patients were treated for 44 weeks with either the IL-23p19 inhibitor or the IL-17A inhibitor and ...
Psoriasis patients win in battle for superiority of the interleukin inhibitors
By Mardi Chapman
23 Aug 2019